key: cord-0016365-ovlgqa86
authors: Blumenthal, Kimberly G.; Castells, Mariana; Banerji, Aleena
title: Drug Desensitization in the Covid-19 Pandemic Era: Local Success to Widespread Potential
date: 2021-03-27
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.03.026
sha: 60935f069b8297554d72366f2780f6c943c95274
doc_id: 16365
cord_uid: ovlgqa86

nan

Along with the rise in the development and food and drug administration approval of novel drug therapies in the US, an increasing number of allergic reactions to these new and targeted agents are occurring. These drugs include chemotherapeutics, monoclonal antibodies, and immunotherapies aimed at personalized treatment of a wide range of conditions from cancer and rheumatologic diseases to cystic fibrosis and diabetes. 1 Often these reactions lead to use of second-line therapies that may place patients at risk of inferior treatment outcomes or increased adverse effects. The necessity to avoid a drug because of its potential allergic reaction upon re-exposure impacts disease management, quality of life, and even potentially life expectancy in patients with cancer. 1 However, experience with the management of allergic drug reactions through protocols that permit patients to safely remain on first-line therapy despite an allergic reaction has grown in the past decade. While initial drug desensitization practice was comprised of patients with cancer seeking help after experiencing hypersensitivity reactions (HSRs) to platinum agents, 2 allergy consultation practices have now been tasked with the evaluation of patients who experience reactions that are endlessly diverse in terms of culprit drugs and potentially implicated mechanisms.

While all drugs can cause adverse reactions, the subset of reactions that are immunologicallymediated HSRs, comprise approximately 20%. Immediate HSRs may be IgE-mediated HSRs, with classic symptoms such as flushing, itching, palmar erythema, urticaria, angioedema, hypotension, and anaphylaxis; for some drugs, skin test positivity suggests possibility of an IgEmediated mechanism. Prior exposure (for "priming") is often necessary for an IgE-mediated mechanism, but we recently learned of notable exceptions where there are pre-existing antibodies (e.g., cetuximab reactions) or environmental sensitizations (e.g., taxane reactions) that permit IgE-mediated allergy to occur with the first dose. 3 However, some immediate HSRs may be non-IgE-mediated, potentially due to direct activation of mast cells. For the majority of HSRs that are immediate in onset and occur despite usual recommended premedication(s), desensitization can be safely and successfully used.

Desensitization, also termed an induction of tolerance procedure, is the gradual introduction of increasing amounts of a drug, leading to induction of temporary tolerance of that drug despite a prior allergic reaction. Reported over 60 years ago, the first desensitization was to penicillin and became the prototype for modern desensitization protocols. While immunologic activation may occur during desensitization, inhibitory mechanisms protect against anaphylaxis and the majority of patients reach the therapeutic dose without harm. 1 In vitro models suggest that IgE desensitization is an antigen-specific process (i.e., desensitization to a drug applies only to that specific drug) that blocks calcium flux, thereby affecting antigen/IgE/FcεRI complex internalization and preventing mast cell mediator release and HSR. 3 In vitro models support our clinical desensitization protocols which include the doubling of antigen doses, delivered with at least 10-minute intervals and starting at 1/1000 the target dose, to elicit inhibitory mechanisms preventing mast cell activation and blocking mediator release. 3 Desensitization also appears effective for HSRs that are not IgE-mediated, but the mechanism remains unclear.

With the assistance of standardized desensitization protocols, patients can continue to safely receive first-line drugs that are recommended for disease treatment. We and others have implemented thousands of desensitization protocols with success across diverse conditions and drug classes. While the largest experience still lies with patients with gynecologic cancers and HSRs to the platin drugs carboplatin, cisplatin, and oxaliplatin, desensitizations have now been successfully performed to a myriad of agents, including taxanes (paclitaxel, docitaxel); doxorubicin; 5FU; irinotecan; monoclonal antibodies such as rituximab, cetuximab, infliximab, trastuzumab, omalizumab, crizotinib; even clinical trial drugs when permitted by the trial protocol (Figure 1, A) .

permits safe and on-schedule first-line treatments. 1,2,4 Drug desensitization is particularly important when the offending drug is the treatment of choice or the alternative drugs have a higher chance of treatment failure and/or unacceptable adverse effects. However, there is limited knowledge about the success of desensitization and switching to an alternative drug remains the most common choice when a patient experiences a HSR, in part because of lack of awareness of this procedure from other specialties and/or lack of access to allergy specialists to evaluate patients for desensitization. 1, 5 Additional barriers to more widespread use of desensitization include lack of appropriate space and staffing for performing desensitization.

Although many areas of allergy/immunology clinical practice have been negatively impacted by the COVID-19 pandemic, in our two Boston-based academic medical centers, drug desensitization has not (Figure 1, B) . Indeed, the total desensitizations in 2020 were greater than in many prior years and mean desensitizations were 120 monthly prior to COVID-19 onset and 136 monthly after COVID-19 onset. Additionally, as the use of tele-health options including telemedicine and electronic consults for drug allergy has expand, 6,7 we envision new possibilities for patients who have HSRs to a first-line cancer or autoimmune disease therapy. While patients used to drive for hours for an evaluation for desensitization, they can now be assessed virtually by a drug allergy specialist, although state regulations may limit some practices across state lines.

More widespread access to desensitization will permit the establishment of specific collaboration efforts between allergists, the consulting physician, and trained pharmacists.

Allergy specialist guidance and oversight, either in-person or virtual, is necessary for all desensitizations since severe allergic outcomes have been described and management of HSRs during desensitization requires specific expertise. Drug desensitization should not be performed when equally effective alternative therapies are available. However, with over 5000 published successful desensitizations with decades of safety data and no fatalities, and with telemedicine normalized into day-to-day practice, we envision that 2021 will be the year where drug desensitizations can spread beyond the specialized academic medical centers. Physicians from specialties including oncology, gastroenterology, neurology, and rheumatology can refer patients for allergy assessment and potential desensitization after immediate reactions to drugs that represent a clear optimal treatment for their patient's condition. By partnering with allergists, these specialists can improve access to first-line treatments for cancer, vasculitis, and other severe chronic conditions by improving knowledge of, and access to, drug desensitization. 

Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies

Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management

Drug hypersensitivity and desensitizations: Mechanisms and new approaches

Platin chemotherapy hypersensitivity reactions: Expanding the scope of practice and improving care

Penicillin allergy evaluation access: A national survey

The use of telemedicine for penicillin allergy skin testing